Isolation perfusion for malignant melanoma of the extremity: a review.

The role of perfusion, normothermic and hyperthermic, in the curative treatment of melanoma remains controversial. Survival appears to be somewhat improved over that of surgery alone in all stages, especially with hyperthermic perfusion, but all comparisons have been retrospective and uncontrolled. In addition to the usual problems with historical controls, melanoma presents its own special problems because of its unpredictable natural history in any given individual and the multiplicity of factors known to affect prognosis. It is unfortunate that hundreds of patients have been treated in uncontrolled studies. Randomized trials continue to be necessary to define this role and even then careful attention will have to be paid to the distribution of known prognostic factors in each group to insure a comparable cohort of patients. The response of melanoma to perfusion is clearly significant, however, and the response rate seems to be improved with hyperthermic perfusion. Hyperthermic perfusion appears to be a useful palliative treatment for locally advanced melanoma of the extremity, especially for which the alternative surgical therapy would be amputation.

[1]  T. K. Das Gupta,et al.  Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities. , 1985, Cancer research.

[2]  G. Coleman,et al.  Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review , 1983, Cancer.

[3]  J. Oosterhuis,et al.  Indications for elective groin dissection in clinical stage I patients with malignant melanoma of the lower extremity treated by hyperthermic regional perfusion , 1983, Cancer.

[4]  N. Cascinelli,et al.  Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities , 1982, Cancer.

[5]  H. Schraffordt koops,et al.  Regional perfusion in the treatment of patients with a locally metastasized malignant melanoma of the limbs. , 1981, European journal of cancer.

[6]  D. Vistica,et al.  Carrier mechanism and specificity accounting for the increase in intracellular melphalan by the basic amino acids. , 1981, Molecular pharmacology.

[7]  G. Westbury,et al.  Isolated limb perfusion for malignant melanoma. , 1980, The Practitioner.

[8]  C. Jamieson,et al.  Isolated limb perfusion with melphalan in the treatment of malignant melanoma , 1980, The British journal of surgery.

[9]  P. Jönsson,et al.  Hyperthermic perfusion of recurrent malignant melanoma on the extremities. , 1980, Acta chirurgica Scandinavica.

[10]  P. Hermanek,et al.  Cytotoxics and hyperthermic perfusion: a preliminary study. , 1979, Cancer treatment reviews.

[11]  M. Rabinovitz,et al.  Amino acid conferred protection against melphalan interference with melphalan therapy by L-leucine, a competitive substrate for transport. , 1979, Cancer letters.

[12]  C. Balch,et al.  A Multifactorial Analysis of Melanoma: Prognostic Histopathological Features Comparing Clark's and Breslow's Staging Methods , 1978, Annals of surgery.

[13]  D. Alberts,et al.  Hydrolysis and protein binding of melphalan. , 1978, Journal of pharmaceutical sciences.

[14]  D. Alberts,et al.  High-pressure liquid chromatographic analysis of melphalan in plasma. , 1978, Journal of pharmaceutical sciences.

[15]  B. Mondovì,et al.  Selective Heat Sensitivity of Cancer Cells , 1977, Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer.

[16]  E. Sugarbaker,et al.  Survival and regional disease control after isolation‐perfusion for invasive stage I melanoma of the extremities , 1976, Cancer.

[17]  B. Giovanella,et al.  Results of hyperthermic perfusion for melanoma of the extremities. , 1975, Surgery, gynecology & obstetrics.

[18]  J. Mccarthy,et al.  The Role of Groin Dissection in the Management of Melanoma of the Lower Extremity , 1974, Annals of surgery.

[19]  J. Shah,et al.  Prognostic significance of lymph node dissection in the treatment of malignant melanoma , 1970, Cancer.

[20]  Stehlin Js,et al.  Hyperthermic perfusion with chemotherapy for cancers of the extremities. , 1969 .

[21]  N. Davis,et al.  A retrospective survey of 498 patients with malignant melanoma. , 1968, Surgery, gynecology & obstetrics.

[22]  J. Stehlin,et al.  MELANOMA OF THE EXTREMITIES. , 1965, American journal of surgery.

[23]  J. Stehlin,et al.  MELANOMA OF THE EXTREMITIES; EXPERIENCES WITH CONVENTIONAL TREATMENT AND PERFUSION IN 339 CASES. , 1965, American journal of surgery.

[24]  T. Dasgupta,et al.  PROGNOSIS IN MALIGNANT MELANOMA. , 1964, Surgery.

[25]  J. Fortner,et al.  RESULTS OF GROIN DISSECTION FOR MALIGNANT MELANOMA IN 220 PATIENTS. , 1964, Surgery.

[26]  J. Stehlin,et al.  Perfusion for malignant melanoma of the extremities. , 1963, American journal of surgery.

[27]  R. F. Ryan.  Chemotherapy perfusion techniques and problems. , 1962, The Surgical clinics of North America.

[28]  R. F. Ryan,et al.  Chemotherapy of Cancer: Regional Perfusion Utilizing an Extracorporeal Circuit , 1958, Annals of surgery.

[29]  T. Winship,et al.  Fractionated intra-arterial cancer; chemotherapy with methyl bis amine hydrochloride; a preliminary report. , 1950, Transactions of the ... Meeting of the American Surgical Association. American Surgical Association. Meeting.